Weekly Closed-End Fund Roundup (October 18, 2026)Seeking Alpha · 7 hr ago
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous NephropathyPRNewsWire · 12 hr ago
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' DiseasePRNewsWire · Oct 8, 2026
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026PRNewsWire · Sep 28, 2026
BlackRock Virginia Municipal Bond Trust (NYSEAMERICAN:BHV) Shares Pass Below 50 Day Moving Average – Here’s What HappenedDefense World · Sep 5, 2026
Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And MoreSeeking Alpha · Aug 27, 2026The BlackRock Virginia Municipal Bond Trust (BHV) functions as a closed-end mutual fund, concentrating its investments within the fixed-income sector. Launched by BlackRock, Inc., the fund's investment management is handled by BlackRock Advisors, LLC. It primarily directs its capital towards the U.S. fixed income market, with a special focus on high-quality, investment-grade municipal bonds.